New experimental modalities in the control of neoplasia
Author(s)
Bibliographic Information
New experimental modalities in the control of neoplasia
(NATO ASI series, ser. A . Life sciences ; v. 120)
Plenum Press, c1986
Available at 6 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
"Proceedings of a NATO Advanced Study Institute on New Experimental Modalities in the Control of Neoplasia, held September 23-October 3, 1985, in Maratea, Italy"--T.p. verso
"Published in cooperation with NATO Scientific Affairs Division."
Includes bibliographies and index
Description and Table of Contents
Description
Acquisition of new knowledge about the biological and bio- chemical nature of neoplastic cells has led to the design and development of several experimental approaches in the tre&tment of cancer. These approaches emerge from the recent work in tu- mor virology, e. g. the control of vital cellular genes by viral regulatory signals; the implication of monoclonal antibodies as a vehicle for the targeted drug delivery and selective de- struction of tumor cells; immunologic advances in the recog- nition of some specific events during metastatic growth; the role of biological response modifiers in modifying or rever- sing malignant growth; and biochemical advances, such as the role of gene amplification in drug resistance and the app- roaches to the reversal of resistance in drug refractory cancer, the role of membranes in designing useful strategies, the identification of new enzymic targets in some types of cancer cells, and the characterization of metabolically active forms of cytostatic compounds.
These are the important issues which were addressed in an international NATO Advanced Study Institute (ASI) attended by scientists from allover the world representing a wide spectrum of scientific disciplines. Although the acquired immune deficiency syndrome (AIDS) is not a malignant disease, but the etiological involvement of a retrovirus belonging to the family of human T-cell lympho- tropic viruses which cause leukemia and lymphomas in man, justifies its inclusion in the agenda of this Study Institute. Scientific presentations from Drs.
Table of Contents
1. A Developmental Biologist's View of Cancer.- 2. Oncogenes in Development, Neoplasia and Evolution.- 3. Acquisition of Metastatic Properties via Somatic Cell Fusion: Implications for Tumor Progression in vivo.- 4. Oncogenes and Tyrosine Kinase Activities as a Function of the Metastatic Phenotype.- 5. Immune Reactivities During the Precancer and Early Cancer Periods: Novel Approaches for Immunomodulation.- 6. Immunomodulation of Tumor Metastases.- 7. Monoclonal Antibody Targeting of Anti-Cancer Agents.- 8. Treatment of Human B Cell Lymphoma with Monoclonal Anti-Idiotype Antiboaies.- 9. Human Monoclonal Antibodies Directed Against HuMTV Antigens form Human Breast Cancer Cells.- 10. Recent Advances in Thymic Hormone Research.- 11. T-Cell Growth Factor (Interleukin -2).- 12. Drug Resistance: New Approaches to Treatment.- 13. Mechanisms of Membrane-Mediated Cytotoxicity by Adriamycin.- 14. Terminal Transferase and Adenosine Deaminase Activities in Human Neoplasia: Their Role in Modulating Cancer Treatment.- 15. Inhibitors of Terminal Transerase: A New Strategy for the Treatment of Human Leukemia.- 16. DNA-Protein Crosslinking of Platinum Coordination Complex in Living Cells: Implication to Evaluate the Cytotoxic Effects of Chemotherapeutic Agents.- 17. Antitumor Activity, Pharmacology and Clinical Trials of Elliptinium (NSC 264-137).- 18. Therapeutic Efficacy of Oxazaphosphorines by Immunomodulation.- 19. The Role of Cellular Glutathione in Protecting Mammalian Cells from X Radiation and Chemotherapy Agents in vitro.- 20. The Role of Papilloma Viruses in Human Cancer.- 21 Anti-Viral Vaccine Control of EB Virus-Associated Cancers.- 22. Bovine Leukosis Virus as a Model for Human Retroviruses.- 23. Human T-Lymphotropic Retroviruses and their Role in Human Diseases.- 24. Molecular Biology of the Human T-Lymphotropic Retroviruses.- 25. Antiviral Approaches in the Treatment of Acquired Immune Deficiency Syndrome.- 26. Inhibition of HTLV-III Replication in Cell Cultures.- 27. Proteins Encoded by the Human T-Lymphotropic Virus Type III/Lymphadenopathy Associated Virus (HTLV-III/LAV) Genes.- 28. Cytopathogenic Mechanisms which Lead to Cell Death of HTLV-III Infected T. Cells.- 29. Clinical Aspects of Thymic Factors in the Treatment of Immunodeficiency Diseases and Neoplasia: Achievements and Failures.- 30. An Overview of the Current Understanding and Management of the Non-Hodgkin's Lymphomas.- Participants.
by "Nielsen BookData"